MetLife Investment Management LLC Has $17.09 Million Position in Becton, Dickinson and Company $BDX

Key Points

• MetLife Investment Management LLC reduced its stake in Becton, Dickinson and Company by 2.5%, now holding 74,614 shares valued at approximately $17.1 million.
• Several large investors, including Vanguard Group and T. Rowe Price, increased their stakes in Becton, Dickinson, with Vanguard now owning 28 million shares, valued around $6.41 billion.
• Becton, Dickinson and Company reported a quarterly EPS of $3.68, exceeding analysts' expectations, with a declared dividend of $1.04 per share, yielding 2.1% annually.

MetLife Investment Management LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 2.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,614 shares of the medical instruments supplier's stock after selling 1,891 shares during the period. MetLife Investment Management LLC's holdings in Becton, Dickinson and Company were worth $17,091,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 4.7% during the 1st quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock valued at $2,880,510,000 after buying an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after buying an additional 667,957 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after buying an additional 312,124 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,091,149 shares of the medical instruments supplier's stock valued at $707,872,000 after purchasing an additional 37,733 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Price Performance

BDX stock traded up $1.59 during midday trading on Friday, reaching $192.84. 1,312,340 shares of the company's stock traded hands, compared to its average volume of 2,615,145. The company has a market cap of $55.27 billion, a price-to-earnings ratio of 34.68, a PEG ratio of 1.46 and a beta of 0.20. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a 50-day simple moving average of $182.58 and a two-hundred day simple moving average of $194.52.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Wells Fargo & Company increased their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their target price for the stock from $217.00 to $185.00 in a research report on Thursday, May 22nd. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Wall Street Zen raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $211.44.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares of the company's stock, valued at approximately $783,194.25. The trade was a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.